1-3 of 3
Peter R. Baum
Close
Sort by
Journal Articles

Role of CD37 SMIP a Novel Engineered Small Modular Immunopharmaceutical in the Treatment of CLL.

Rosa Lapalombella, PhD, Xiaobin B. Zhao, PhD, Peter R. Baum, PhD, Jeffrey A. Ledbetter, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2007) 110 (11): 801.
https://doi.org/10.1182/blood.V110.11.801.801
Published: 2007
Journal Articles

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

Xiaobin Zhao, Rosa Lapalombella, Trupti Joshi, Carolyn Cheney, Aruna Gowda, Martha S. Hayden-Ledbetter, Peter R. Baum, Thomas S. Lin, David Jarjoura, Amy Lehman, Donna Kussewitt, Robert J. Lee, Michael A. Caligiuri, Susheela Tridandapani, Natarajan Muthusamy, John C. Byrd
Journal: Blood
Blood (2007) 110 (7): 2569–2577.
https://doi.org/10.1182/blood-2006-12-062927
Published: 2007
Journal Articles

NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL.

Xiaobin B. Zhao, MS, Joshi Trupti, B.S., Rosa Lapalombella, Ph. D., Carolyn Cheney, B.S., Aruna Gowda, M.D., Martha S. Hayden-Ledbetter, Ph. D., Peter R. Baum, Ph.D., Thomas S. Lin, M.D., Ph.D., David Jarjoura, Ph.D., Amy Lehman, M.S., Robert J. Lee, Ph.D., Michael A. Caligiuri, M.D., Susheela Tridandapani, Ph.D., Natarajan Muthusamy, Ph.D., John C. Byrd, M.D.
Journal: Blood
Blood (2006) 108 (11): 135.
https://doi.org/10.1182/blood.V108.11.135.135
Published: 2006